Related Experiment Video
Updated: Sep 24, 2025
07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
537
[Intermediate-high risk pulmonary embolism: identification and treatment]
N M Jager1,2, M M M Eijsvogel3, M Wagenaar3
1Medisch Spectrum Twente, Intensive Care,Enschede.
Nederlands Tijdschrift Voor Geneeskunde
|May 2, 2022
Summary
Optimal treatment for intermediate-high risk pulmonary embolism is crucial to prevent mortality. Treatment choices, including anticoagulation, systemic thrombolysis, or catheter-guided thrombolysis, depend on patient stability and response.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Critical Care Medicine
Background:
- Intermediate-high risk pulmonary embolism presents with diverse clinical symptoms.
- Effective management is vital to reduce short-term mortality in these patients.
Purpose of the Study:
- To review optimal treatment strategies for intermediate-high risk pulmonary embolism.
- To highlight decision-making challenges and the role of pulmonary embolism response teams.
Main Methods:
- Review of current guidelines and treatment recommendations.
- Analysis of therapeutic options including anticoagulation, systemic thrombolysis, and catheter-guided thrombolysis.
- Discussion of factors influencing treatment choice and timing.
Main Results:
- Standard anticoagulation is the first-line treatment for hemodynamically stable patients.
- Systemic thrombolysis is indicated for circulatory deterioration or lack of response to anticoagulation.
- Catheter-guided thrombolysis is reserved for contraindications or treatment failure with systemic thrombolysis.
Conclusions:
- Treatment decisions for intermediate-high risk pulmonary embolism require careful consideration of clinical status and response.
- Pulmonary embolism response teams can aid in optimizing treatment selection and timing.
- Timely and appropriate intervention is key to improving outcomes.
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
55
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
55
01:27Pulmonary Embolism III: Nursing Management
53
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
53
01:29Pulmonary Embolism I: Introduction
70
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
70
01:29Venous Thrombosis III: Interprofessional Care
33
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
33
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
264
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
264
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
234
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
234